Libtayo (cemiplimab) - Regeneron Sales History and Forecasts

Regeneron Libtayo

Chart

Sales

Snapshot

QoQ

T&Ds

Alerts

Marketed

Infusion

Anti-PD1/PD-L1

Cutaneous squamous cell carcinoma

Cancer - Solid Tumour

NSCLC - Non small cell lung cancer

BCC - Basal Cell Carcinoma

Loading quarterly data...

Consensus

Lower than Low

Lower than Median

Equal

Higher than Median

Higher than High

Actual (No Consensus)

	Median	YOY	High	Low	US	YOY	RoW	YOY

Libtayo is also known as cemiplimab, REGN2810.

Medicare Part B spending of $155m in 2020 represented 57.4% of WW sales.

Excel Plugin ID: DRUG-1975

DrugAnalyst Database